Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12624001059550
Ethics application status
Approved
Date submitted
25/07/2024
Date registered
2/09/2024
Date last updated
2/09/2024
Date data sharing statement initially provided
2/09/2024
Type of registration
Prospectively registered
Titles & IDs
Public title
The Enhanced Dementia Diagnosis (EDD study) study-Evaluating new diagnostics for Alzheimer's Disease against usual care for people attending memory clinics within Australia.
Query!
Scientific title
The EDD study-Evaluating new diagnostics for Alzheimer's Disease against usual care for people attending memory clinics within Australia.
Query!
Secondary ID [1]
312760
0
None
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
EDD
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Dementia
334430
0
Query!
Condition category
Condition code
Neurological
331058
331058
0
0
Query!
Dementias
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
We propose to test the Enhanced Dementia Diagnosis (EDD) program in clinical services in Australia. To participate in this study, people undergoing a diagnostic work up for dementia will donate blood for novel biomarker measurements and undergo a digital cognitive assessment and brain scans. We will collect 2 blood samples of no more than 100ml each. We will complete 2 brain MRIs (30 minutes each), and a single Amyloid PET scan (30-40 minutes) (the PET radiotracer administered intravenously, 200MBq once only). All tests will be conducted by EDD study staff. The EDD program tests will occur on a single day, or over two days, at the research facility (total time <6 h). This will occur, at baseline, and again at 12 months. Completion of these tests will be recorded using study databases to monitor adherence. These diagnostics will be provided to physicians who care for the enrolled patients. The influence of these biomarkers on dementia diagnosis will be assessed. These diagnostics will be collected again at 12 months. Participants (memory clinic doctors, patients and their care partners) will also be requested to complete specific surveys at different timepoints and will be invited to participate in an interview.
Query!
Intervention code [1]
329061
0
Diagnosis / Prognosis
Query!
Comparator / control treatment
This is a Before and After study…patients are their own control. The usual care process for dementia diagnosis varies between clinical services and varies according to clinical and non-clinical attributes of the patient. Typically, the usual care for dementia diagnosis involves clinical patient assessment, routine blood tests, brain MRI, a traditional neuropsychology assessment and/or FDG-PET conducted over different time-points following referral to a memory clinic. For the EDD study, the EDD program tests will occur in parallel with the dementia diagnosis process under usual care.
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
338828
0
The concordance of a blood biomarker for Alzheimer's disease with a diagnosis of Alzheimer's disease conducted under usual care.
Query!
Assessment method [1]
338828
0
Blood test conducted in a certified laboratory using an assay regarded specific for Alzheimer's disease.
Under the usual care diagnosis process, the following assessments may or may not be relied upon by the diagnosing clinician: a physician assessment, routine blood tests, brain MRI, a traditional neuropsychology assessment and/or FDG-PET.
Query!
Timepoint [1]
338828
0
The outcome will be assessed at the individual and aggregate level. Baseline blood biomarker testing will be conducted at point of diagnosis, and at 12 months post baseline.
Under usual care, a diagnosis of Alzheimer's disease is typically made within 3-6 months of assessment at a memory clinic.
Query!
Primary outcome [2]
338829
0
The concordance of a quantitative brain MRI report for Alzheimer's disease with a diagnosis of Alzheimer's disease conducted under usual care.
Query!
Assessment method [2]
338829
0
Brain MRI and accompanying quantitative report.
Under the usual care diagnosis process the following assessments may or may not be relied upon by the diagnosing clinician: a physician assessment, routine blood tests, brain MRI, a traditional neuropsychology assessment and/or FDG-PET.
Query!
Timepoint [2]
338829
0
The outcome will be assessed at the individual and aggregate level. The brain MRI will be conducted at point of diagnosis (baseline), and at 12 months post baseline.
Under usual care, a diagnosis of Alzheimer's disease is typically made within 3-6 months of assessment at a memory clinic.
Query!
Primary outcome [3]
338889
0
Concordance of a digital cognitive test with the traditional cognitive test.
Query!
Assessment method [3]
338889
0
A battery of cognitive tests delivered together that are: Montreal Cognitive Assessment (MoCA), International Shopping List Test (ISLT), International Digit Symbol Substitution – Medicines (iDSST – Medicines), Cogstate Brief Battery, Cognitive Function Instrument (CFI), Depression Anxiety & Stress Scale – 21 item version (DASS-21)(This scale will only be administered to participants aged younger than 65 years), Geriatric Depression Inventory – Short Form (GDS-15)(This scale will only be administered to participants aged 65 years or older), Geriatric Anxiety Inventory (GAI)(This scale will only be administered to participants aged 65 years or older), Alcohol Use Disorders Identification Test (AUDIT-C),Healthy Brain Ageing – Functional Assessment Questionnaire (HBA-FAQ).
Tests developed by the team (not validated): Pre-Assessment Survey; Follow-Up Assessment Questionnaire (only administered at 12 months follow up); Rater Observational Scale (Cognitive test assessor only completes this).
Digital Cognitive test:
International Shopping List Test (ISLT)
International Digit Symbol Substitution – Medicines (iDSST – Medicines)
Cogstate Brief Battery
Cognitive Function Instrument (CFI)
Healthy Brain Ageing – Functional Assessment Questionnaire (HBA-FAQ)
Pre-Assessment Survey
Follow-Up Assessment Questionnaire
Rater Observational Scale
Traditional Cognitive test
Montreal Cognitive Assessment (MoCA)
Depression Anxiety & Stress Scale – 21 item version (DASS-21)
Geriatric Depression Inventory – Short Form (GDS-15)
Geriatric Anxiety Inventory (GAI)
Alcohol Use Disorders Identification Test (AUDIT-C)
Query!
Timepoint [3]
338889
0
The outcome will be assessed at the individual and aggregate level. The cognitive test battery will be conducted at point of diagnosis (baseline), and at 12 months post baseline.
Query!
Secondary outcome [1]
437803
0
Memory clinic physician acceptability of EDD program
Query!
Assessment method [1]
437803
0
A 'physician diagnosis survey' that has been designed specifically for this study.
Query!
Timepoint [1]
437803
0
The outcome will be assessed at the individual and aggregate level. At point of diagnosis (baseline), single time-point only.
Query!
Secondary outcome [2]
438629
0
Patient and / or care partner acceptability of the EDD program
Query!
Assessment method [2]
438629
0
A feedback survey designed specifically for the study administered by the EDD study team.
Query!
Timepoint [2]
438629
0
At point of diagnosis only.
Query!
Secondary outcome [3]
438630
0
Patient and / or care partner acceptability of the EDD program.
Query!
Assessment method [3]
438630
0
A single semi-structured interview conducted face to face administered by the EDD study team.
Query!
Timepoint [3]
438630
0
At point of diagnosis only.
Query!
Eligibility
Key inclusion criteria
1) Memory clinic physicians, (2) Memory clinic patients being considered for a diagnosis of Mild Cognitive Impairment or Alzheimer’s disease dementia, and (3) Patients’ care partners.
1) Memory clinic physicians
Specialists (or trainee specialists) who diagnose dementia as part of their usual clinical practice’, private or public.
2) Memory clinic patients
1. Age is greater than or equal to 40 years.
2. Attending a memory clinic seeking assessment for cognitive concerns or dementia.
3. Individuals assessed with dementia have an identified care partner (e.g., family member, spouse, caregiver).
3)Memory clinic patients care partner
An individual, aged over 18, who is nominated as a care partner by the patient.
Query!
Minimum age
40
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1) Memory clinic physicians
Not practicing in an EDD program participating memory clinic.
2) Memory clinic patients
1. Memory clinic physician assesses the patient as unsuitable for dementia diagnostic workup, based on:
a. No evidence of cognitive or behavioural impairment.
b. Potential patient has severe dementia or other illness such that the person will receive no benefit from undergoing further investigation in the opinion of the memory clinic physician.
2. Patient and/or ‘care partner’ is unable or unwilling to provide informed consent for the study.
3. Amyloid pathology status obtained by PET/CSF/Blood are already known to the memory clinic physician.
4. The patient is unable to undergo Aß-PET and FDG-PET.
5. Individuals with advanced care directive that is in potential conflict with consent, for e.g., “I don’t want to be involved in research studies”.
Query!
Study design
Purpose of the study
Diagnosis
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Other
Query!
Other design features
All participants receive the same treatment and act as their own control with a comparison being made between the Enhanced Dementia Diagnosis program and diagnoses made as part of usual care.
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Date of first participant enrolment
Anticipated
7/09/2024
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
500
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Recruitment hospital [1]
26809
0
Austin Health - Heidelberg Repatriation Hospital - Heidelberg West
Query!
Recruitment hospital [2]
26845
0
Western Hospital - Footscray - Footscray
Query!
Recruitment hospital [3]
26846
0
Barwon Health - McKellar Centre campus - North Geelong
Query!
Recruitment hospital [4]
26847
0
Kingston Centre - Cheltenham
Query!
Recruitment hospital [5]
26855
0
Ballarat Health Services - Queen Elizabeth Centre - Ballarat
Query!
Recruitment postcode(s) [1]
42860
0
3081 - Heidelberg West
Query!
Recruitment postcode(s) [2]
42907
0
3011 - Footscray
Query!
Recruitment postcode(s) [3]
42908
0
3215 - North Geelong
Query!
Recruitment postcode(s) [4]
42909
0
3192 - Cheltenham
Query!
Recruitment postcode(s) [5]
42916
0
3350 - Ballarat
Query!
Funding & Sponsors
Funding source category [1]
316971
0
Government body
Query!
Name [1]
316971
0
NHMRC
Query!
Address [1]
316971
0
Query!
Country [1]
316971
0
Australia
Query!
Funding source category [2]
316972
0
Government body
Query!
Name [2]
316972
0
Australian Department of Health and Aged Care, Medical Research Future Fund (MRFF)
Query!
Address [2]
316972
0
Query!
Country [2]
316972
0
Australia
Query!
Primary sponsor type
Other
Query!
Name
The Florey Institute of Neuroscience and Mental Health
Query!
Address
Query!
Country
Australia
Query!
Secondary sponsor category [1]
319220
0
None
Query!
Name [1]
319220
0
Query!
Address [1]
319220
0
Query!
Country [1]
319220
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
315726
0
Austin Health Human Research Ethics Committee
Query!
Ethics committee address [1]
315726
0
https://www.austin.org.au/Office-for-Research/
Query!
Ethics committee country [1]
315726
0
Australia
Query!
Date submitted for ethics approval [1]
315726
0
Query!
Approval date [1]
315726
0
24/05/2024
Query!
Ethics approval number [1]
315726
0
HREC/103365/Austin-2023
Query!
Summary
Brief summary
It is difficult for skilled clinicians to diagnose Alzheimer’s disease in the early stages. A diagnosis of Alzheimer’s disease also requires evidence of a particular type of brain pathology by using a specialized brain scan. The EDD study has been devised as a comprehensive solution to address current diagnostic challenges. The EDD study is integrated into existing clinical services, with the aim of providing clinicians with data on pathology, brain damage, and brain function through advanced blood diagnostics, advanced brain-imaging techniques, and in-depth digital cognitive assessments that can be performed via telehealth. This study will assess the accuracy and usefulness of each element of the EDD program using surveys of physicians and patients, and with reference to gold standards.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
135614
0
Prof Scott Ayton
Query!
Address
135614
0
The Florey, Kenneth Myer Building, Parkville, Victoria, 3010.
Query!
Country
135614
0
Australia
Query!
Phone
135614
0
+61 0390356559
Query!
Fax
135614
0
Query!
Email
135614
0
[email protected]
Query!
Contact person for public queries
Name
135615
0
Dr Michelle Shannon
Query!
Address
135615
0
The Florey, Melbourne Brain Centre, 245 Burgundy Street, Heidelberg, Victoria 3084
Query!
Country
135615
0
Australia
Query!
Phone
135615
0
+61 0390357079
Query!
Fax
135615
0
Query!
Email
135615
0
[email protected]
Query!
Contact person for scientific queries
Name
135616
0
Scott Ayton
Query!
Address
135616
0
The Florey, Kenneth Myer Building, Parkville, Victoria 3010
Query!
Country
135616
0
Australia
Query!
Phone
135616
0
+61 0390357079
Query!
Fax
135616
0
Query!
Email
135616
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
For ethical reasons IPD will not be made available
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF